- Q1 2024 Editas Medicine Inc Earnings Call TranscriptMay 08, 2024$5.04 (-11.36%)Earnings
- Q4 2023 Editas Medicine Inc Earnings Call TranscriptFeb 28, 2024$11.07 (+24.94%)Earnings
- Editas Medicine Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Editas Medicine Inc Earnings Call TranscriptNov 03, 2023$8.31 (+18.21%)Earnings
- Editas Medicine Inc at JPMorgan Biotech Fireside Investor Series TranscriptOct 12, 2023
- Editas Medicine Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Editas Medicine Inc at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Q2 2023 Editas Medicine Inc Earnings Call TranscriptAug 02, 2023$9.14 (+5.66%)Earnings
- Editas Medicine Inc RUBY trial of EDIT-301 TranscriptJun 12, 2023
- Editas Medicine Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Editas Medicine Inc Earnings Call TranscriptMay 05, 2023$9.77 (+12.04%)Earnings
- Q4 2022 Editas Medicine Inc Earnings Call TranscriptFeb 22, 2023$9.75 (+6.21%)Earnings
- Editas Medicine Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Editas Medicine Inc EDIT-301 Clinical Update TranscriptDec 06, 2022
- Editas Medicine Inc Announces EDIT-101 Clinical Update Presentation TranscriptNov 17, 2022
- Q3 2022 Editas Medicine Inc Earnings Call TranscriptNov 02, 2022$12.89 (+1.10%)Earnings
- Editas Medicine Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Editas Medicine Inc Earnings Call TranscriptAug 03, 2022$18.69 (+13.41%)Earnings
- Q1 2022 Editas Medicine Inc Earnings Call TranscriptMay 04, 2022$15.81 (+11.50%)Earnings
- Q4 2021 Editas Medicine Inc Earnings Call TranscriptFeb 24, 2022$15.86 (+10.06%)Earnings
- Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Editas Medicine Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Editas Medicine Inc Earnings Call TranscriptNov 08, 2021$40.57 (+8.19%)Earnings
- Editas Medicine Inc EDIT-101 Clinical Data Review Call TranscriptSep 29, 2021
- Editas Medicine Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Q2 2021 Editas Medicine Inc Earnings Call TranscriptAug 04, 2021$46.05 (+9.36%)Earnings
- Editas Medicine Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Q1 2021 Editas Medicine Inc Earnings Call TranscriptMay 05, 2021$34.72 (+0.17%)Earnings
- Editas Medicine Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Editas Medicine Inc Earnings Call TranscriptFeb 25, 2021$44.76 (-9.94%)Earnings
- Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Editas Medicine Inc at Barclays Virtual Gene Editing & Gene Therapy Summit TranscriptNov 16, 2020
- Q3 2020 Editas Medicine Inc Earnings Call TranscriptNov 05, 2020$31.55 (+3.61%)Earnings
- Editas Medicine Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Q2 2020 Editas Medicine Inc Earnings Call TranscriptAug 06, 2020$36.84 (+13.39%)Earnings
- Editas Medicine Inc Annual Shareholders Meeting TranscriptJun 10, 2020
- Q1 2020 Editas Medicine Inc Earnings Call TranscriptMay 07, 2020$24.1 (-3.64%)Earnings
- Q4 2019 Editas Medicine Inc Earnings Call TranscriptFeb 26, 2020$22.41 (-0.31%)Earnings
- Editas Medicine Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Q3 2019 Editas Medicine Inc Earnings Call TranscriptNov 12, 2019$22.32 (+9.47%)Earnings
- Editas Medicine Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
- Q2 2019 Editas Medicine Inc Earnings Call TranscriptAug 06, 2019$24.63 (+2.93%)Earnings
- Q1 2019 Editas Medicine Inc Earnings Call TranscriptMay 07, 2019$24.68 (-4.56%)Earnings
- Editas Medicine Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2019
- Q4 2018 Editas Medicine Inc Earnings Call TranscriptFeb 28, 2019$20.63 (-1.53%)Earnings
Editas Medicine Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Gena Wang. I'm the [SME-cap] biotech analyst at Barclays. It is my great pleasure to introduce our next speakers, Charlie Albright, Chief Scientific Officer from Editas. Also together with us, we have Cindy Collins, Interim CEO with us for Q&A session.
Thank you, Gena. It's a pleasure to be here. Developing innovative medicines with a new technology is an area with great promise. It's also an area with some risk. And for that reason, I'll be making forward-looking statements, and I encourage you to read the slide at your convenience.
Our mission at Editas is to take the incredible power of CRISPR gene editing and turn it into transformational medicines. I want to update you today on where we are on that -- on accomplishing that mission, and I want to start by the progress we've made in 2018.
Certainly, one of the largest things we did last year was to get filed and have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)